Treatment Study for Patients with HER2-Expressing Cancers

Clinical Trial Title

Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have HER2-expressing cancer.
  • Have an ECOG of 0 or 1.
  • Have adequate renal function.
  • Are at least 18 years of age.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Melody A. Cobleigh, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more